Physician profile
Sheldon H Preskorn
NPI 1841252566
$498,340.35
in general payments reported to CMS, 2019-2025
12 companies · $32K in 2025
The $32K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231K · 2020: $24K · 2021: $41K · 2022: $79K · 2023: $86K · 2024: $3,840 · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $80K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Travel and Lodging: $4,707 · Honoraria: $1,320 · Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $79,565.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,080.00 |
| Travel and Lodging | $4,707.08 |
| Honoraria | $1,320.00 |
| Food and Beverage | $793.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $136,256.32 | 2019-2022 | |
| Janssen Research & Development, LLC | $116,282.49 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $78,401.92 | 2019-2020 | |
| Bioxcel Therapeutics, INC. | $73,376.15 | 2023-2025 | Igalmi |
| Alkermes, INC. | $51,890.89 | 2020-2023 | Lybalvi |
| Eisai INC. | $16,279.72 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $10,107.99 | 2021 | |
| Allergan, INC. | $9,681.82 | 2019 | |
| Merck Sharp & Dohme LLC | $4,262.26 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $1,728.00 | 2020 | |
| Abbvie INC. | $60.17 | 2022 | |
| Acadia Pharmaceuticals INC | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Preskorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.